Evidence map›Paper›PMID 40693603›Full record

ReviewChinese medical journal2025

Targeted therapies and immunotherapies for unresectable cholangiocarcinoma.

Shengbai Xue, Weihua Jiang, Jingyu Ma, Haiyan Xu, Yanling Wang, Wenxin Lu, Daiyuan Shentu, Jiujie Cui, Maolan Li, Liwei Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chinese medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. [Immunotherapy and Targeted Therapy for Advanced Biliary Tract Cancer].The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shengbai XueDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Weihua JiangDepartment of Oncology, Punan Hospital in Pudong New District, Shanghai 200125, China.
Jingyu MaDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Haiyan XuDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Yanling WangDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Wenxin LuDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Daiyuan ShentuDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Jiujie CuiDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Maolan LiDepartment of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.
Liwei WangDepartment of Oncology and State Key Laboratory of Systems Medicine for Cancer of Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractCholangiocarcinoma (CCA) is a fatal malignancy with steadily increasing incidence and poor prognosis. Since most CCA cases are diagnosed at an advanced stage, systemic therapies, including chemotherapy, radiotherapy, targeted therapy, and immunotherapy, play a crucial role in the management of unresectable CCA. The recent advances in targeted therapies and immunotherapies brought more options in the clinical management of unresectable CCA. This review depicts the advances of targeted therapies and immunotherapies for unresectable CCA, summarizes crucial clinical trials, and describes the efficacy and safety of different drugs, which may help further develop precision and individualization in the clinical treatment of unresectable CCA.

Indexed as

Bile Duct NeoplasmsCholangiocarcinomaImmunotherapyMolecular Targeted TherapyHumansAdoptive cell therapyCholangiocarcinomaEpidermal growth factor receptorImmune checkpoint inhibitorsImmunotherapyProgrammed cell death 1/ programmed cell death 1 ligand 1Targeted therapyVascular endothelial growth factor

Identifiers

PMID40693603
PMCPMC12369749

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.